Head-to-head · WeighScore
Dr. Gillis' Wellness Center vs Zealthy
The verdict
Dr. Gillis' Wellness Center takes it — 67/100 to 46.7/100.
Dr. Gillis' Wellness Center grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Gillis' Wellness Center is a Maine-based clinic (Oakland) offering nationwide telehealth for GLP-1 weight loss. It prescribes semaglutide, tirzepatide, and retatrutide in both injectable and subli
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Dr. Gillis' Wellness Center | Zealthy |
|---|---|---|
| WeighScore | 67/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #177 | #496 |
| Semaglutide | $149/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #177 · C
Strengths
- Sublingual ODT tablets offered as needle-free alternative
- Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
- Transparent pricing: $150 starting dose, plans from $149/mo
- Led by board-certified physician/surgeon with 25+ years experience
- No contracts; flexible weekly, bi-weekly, or monthly cadence
Where it loses points
- Specific dose-tier pricing beyond starting plan not detailed
- Compounded vs brand not explicitly stated for all meds
- Smaller clinic vs national telehealth brands
- State licensing list not published
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.